247 related articles for article (PubMed ID: 36134588)
1. Prevalence of non-alcoholic fatty liver disease (NAFLD) in a cohort of patients with type 2 diabetes: the PHIGNA-DM2 study.
Martínez-Ortega AJ; Piñar Gutiérrez A; Lara-Romero C; Remón Ruiz PJ; Ampuero-Herrojo J; de Lara-Rodríguez I; Romero-Gómez M; García Luna PP; Soto-Moreno A
Nutr Hosp; 2022 Oct; 39(5):1012-1018. PubMed ID: 36134588
[TBL] [Abstract][Full Text] [Related]
2. Transient elastography for the prevalence of non-alcoholic fatty liver disease in patients with type 2 diabetes: Evidence from the CORDIAL cohort study.
Alfadda AA; Sherbeeni SM; Alqutub AN; Aldosary AS; Aldaghri NM; Taylor-Robinson SD; Alqahtani SA; Gul R; Almaghamsi AM
Saudi J Gastroenterol; 2022; 28(6):426-433. PubMed ID: 35645140
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of steatosis and fibrosis in young adults in the UK: a population-based study.
Abeysekera KWM; Fernandes GS; Hammerton G; Portal AJ; Gordon FH; Heron J; Hickman M
Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):295-305. PubMed ID: 31954687
[TBL] [Abstract][Full Text] [Related]
4. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
[TBL] [Abstract][Full Text] [Related]
5. Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography.
Lai LL; Wan Yusoff WNI; Vethakkan SR; Nik Mustapha NR; Mahadeva S; Chan WK
J Gastroenterol Hepatol; 2019 Aug; 34(8):1396-1403. PubMed ID: 30551263
[TBL] [Abstract][Full Text] [Related]
6. Screening for hepatic fibrosis and steatosis in Turkish patients with type 2 diabetes mellitus: A transient elastography study.
Demir M; Deyneli O; Yılmaz Y
Turk J Gastroenterol; 2019 Mar; 30(3):266-270. PubMed ID: 30411703
[TBL] [Abstract][Full Text] [Related]
7. Simultaneously Screening for Liver Steatosis and Fibrosis in Romanian Type 2 Diabetes Mellitus Patients Using Vibration-Controlled Transient Elastography with Controlled Attenuation Parameter.
Trifan A; Stratina E; Nastasa R; Rotaru A; Stafie R; Zenovia S; Huiban L; Sfarti C; Cojocariu C; Cuciureanu T; Muzica C; Chiriac S; Girleanu I; Singeap AM; Stanciu C
Diagnostics (Basel); 2022 Jul; 12(7):. PubMed ID: 35885657
[TBL] [Abstract][Full Text] [Related]
8. Transient elastography and controlled attenuation parameter to evaluate hepatic steatosis and liver stiffness in postpartum patients.
Hussain FN; Rosenbluth E; Feldman KM; Strauss TS; Schneider E; Schmidt-Beauchat E; Rodriguez-Rivas C; Brustman L; Kushner T
J Matern Fetal Neonatal Med; 2023 Dec; 36(1):2190838. PubMed ID: 36935368
[TBL] [Abstract][Full Text] [Related]
9. Liver Stiffness Evaluation by Transient Elastography in Type 2 Diabetes Mellitus Patients with Ultrasound-proven Steatosis.
Sporea I; Mare R; Lupușoru R; Sima A; Sirli R; Popescu A; Timar R
J Gastrointestin Liver Dis; 2016 Jun; 25(2):167-74. PubMed ID: 27308647
[TBL] [Abstract][Full Text] [Related]
10. Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients.
Garg H; Aggarwal S; Shalimar ; Yadav R; Datta Gupta S; Agarwal L; Agarwal S
Surg Obes Relat Dis; 2018 Jan; 14(1):81-91. PubMed ID: 29126863
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of liver fibrosis and steatosis by transient elastography for cardiovascular and mortality outcomes in individuals with nonalcoholic fatty liver disease and type 2 diabetes: the Rio de Janeiro Cohort Study.
Cardoso CRL; Villela-Nogueira CA; Leite NC; Salles GF
Cardiovasc Diabetol; 2021 Sep; 20(1):193. PubMed ID: 34560854
[TBL] [Abstract][Full Text] [Related]
12. Ultrasound and FibroScan
Salmi A; di Filippo L; Ferrari C; Frara S; Giustina A
Endocrine; 2022 Nov; 78(2):262-269. PubMed ID: 35980569
[TBL] [Abstract][Full Text] [Related]
13. Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening.
Lomonaco R; Godinez Leiva E; Bril F; Shrestha S; Mansour L; Budd J; Portillo Romero J; Schmidt S; Chang KL; Samraj G; Malaty J; Huber K; Bedossa P; Kalavalapalli S; Marte J; Barb D; Poulton D; Fanous N; Cusi K
Diabetes Care; 2021 Feb; 44(2):399-406. PubMed ID: 33355256
[TBL] [Abstract][Full Text] [Related]
14. The prevalence of alcoholic and nonalcoholic fatty liver disease in adolescents and young adults in the United States: analysis of the NHANES database.
Alkhouri N; Almomani A; Le P; Payne JY; Asaad I; Sakkal C; Vos M; Noureddin M; Kumar P
BMC Gastroenterol; 2022 Jul; 22(1):366. PubMed ID: 35907827
[TBL] [Abstract][Full Text] [Related]
15. Atherogenic dyslipidemia, but not hyperglycemia, is an independent factor associated with liver fibrosis in subjects with type 2 diabetes and NAFLD: a population-based study.
Julián MT; Pera G; Soldevila B; Caballería L; Julve J; Puig-Jové C; Morillas R; Torán P; Expósito C; Puig-Domingo M; Castelblanco E; Franch-Nadal J; Cusi K; Mauricio D; Alonso N
Eur J Endocrinol; 2021 Apr; 184(4):587-596. PubMed ID: 33606661
[TBL] [Abstract][Full Text] [Related]
16. High Prevalence of Advanced Liver Fibrosis Assessed by Transient Elastography Among U.S. Adults With Type 2 Diabetes.
Ciardullo S; Monti T; Perseghin G
Diabetes Care; 2021 Feb; 44(2):519-525. PubMed ID: 33303638
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and risk factors of nonalcoholic steatohepatitis with significant fibrosis in people with HIV.
Michel M; Labenz C; Wahl A; Anders M; Armandi A; Huber Y; Galle PR; Sprinzl M; Schattenberg JM
AIDS; 2022 Oct; 36(12):1665-1674. PubMed ID: 35849074
[TBL] [Abstract][Full Text] [Related]
18. Non-alcoholic fatty liver disease (NAFLD) and significant hepatic fibrosis defined by non-invasive assessment in patients with type 2 diabetes.
Sobhonslidsuk A; Pulsombat A; Kaewdoung P; Petraksa S
Asian Pac J Cancer Prev; 2015; 16(5):1789-94. PubMed ID: 25773826
[TBL] [Abstract][Full Text] [Related]
19. Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes.
Ciardullo S; Perseghin G
Metabolism; 2021 Aug; 121():154752. PubMed ID: 33716004
[TBL] [Abstract][Full Text] [Related]
20. Clinical spectrum of non-alcoholic fatty liver disease in patients with diabetes mellitus.
Chen K; Sng WK; Quah JH; Liu J; Chong BY; Lee HK; Wang XF; Tan NC; Chang PE; Tan HC; Bee YM; Goh GBB
PLoS One; 2020; 15(8):e0236977. PubMed ID: 32822391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]